P78371 (TCPB_HUMAN) Homo sapiens (Human)
T-complex protein 1 subunit beta UniProtKBInterProSTRINGInteractive Modelling
Available Structures
49 Experimental Structures
Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
---|---|---|---|---|---|---|
The beta-tubulin folding intermediate II |
Heteromer P07437; P17987; P40227; P48643; P49368; P50990; P50991; Q99832; | 100 | 8×AF3; 8×MG; 8×ADP; | |||
Human TRiC-PhLP2A-actin complex in the closed state |
Heteromer P17987; P40227; P48643; P49368; P50990; P50991; P60709; Q99832; Q9H2J4; | 100 | ||||
Human TRiC complex in closed state with nanobody and tubulin bound |
Heteromer P17987; P40227; P48643; P49368; P50990; P50991; Q13885; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
Human TRiC complex in closed state with nanobody bound (Consensus Map) |
Heteromer P17987; P40227; P48643; P49368; P50990; P50991; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
CCT G beta 5 complex closed state 15 |
Heteromer O14775; P17987; P40227; P48643; P49368; P50990; P50991; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
CCT G beta 5 complex closed state 14 |
Heteromer O14775; P17987; P40227; P48643; P49368; P50990; P50991; Q13371; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
The beta-tubulin folding intermediate I |
Heteromer P07437; P17987; P40227; P48643; P49368; P50990; P50991; Q99832; | 100 | 8×MG; 8×ADP; 8×AF3; | |||
CCT G beta 5 complex closed state 0 |
Heteromer P17987; P40227; P48643; P49368; P50990; P50991; Q13371; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
CCT-G beta 5 complex closed state 7 |
Heteromer O14775; P17987; P40227; P48643; P49368; P50990; P50991; Q13371; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
CCT G beta 5 complex intermediate state |
Heteromer P17987; P40227; P48643; P49368; P50990; P50991; Q99832; | 100 | 16×ADP; | |||
CCT G beta 5 complex close state 11 |
Heteromer O14775; P17987; P40227; P48643; P49368; P50990; P50991; Q13371; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
CCT G beta 5 complex closed state 12 |
Heteromer O14775; P17987; P40227; P48643; P49368; P50990; P50991; Q13371; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
CCT G beta 5 complex closed state 2 |
Heteromer O14775; P17987; P40227; P48643; P49368; P50990; P50991; Q13371; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
CCT-G beta 5 complex closed state 6 |
Heteromer O14775; P17987; P40227; P48643; P49368; P50990; P50991; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
CCT G beta 5 complex closed state 13 |
Heteromer O14775; P17987; P40227; P48643; P49368; P50990; P50991; Q13371; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
The beta-tubulin folding intermediate IV |
Heteromer P07437; P17987; P40227; P48643; P49368; P50990; P50991; Q99832; | 100 | 8×MG; 8×ADP; 8×AF3; | |||
CCT-G beta 5 complex closed state 4 |
Heteromer O14775; P17987; P40227; P48643; P49368; P50990; P50991; Q13371; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
Human TRiC complex in closed state with nanobody Nb18, actin and PhLP2A bound |
Heteromer P17987; P40227; P48643; P49368; P50990; P50991; P63261; Q99832; Q9H2J4; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
CCT G beta 5 complex closed state 9 |
Heteromer O14775; P17987; P40227; P48643; P49368; P50990; P50991; Q13371; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
The beta-tubulin folding intermediate III |
Heteromer P07437; P17987; P40227; P48643; P49368; P50990; P50991; Q99832; | 100 | 8×MG; 8×ADP; 8×AF3; | |||
CCT G beta 5 complex closed state 1 |
Heteromer O14775; P17987; P40227; P48643; P49368; P50990; P50991; Q13371; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
CCT G beta 5 complex closed state 10 |
Heteromer O14775; P17987; P40227; P48643; P49368; P50990; P50991; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
CCT G beta 5 complex closed state 3 |
Heteromer O14775; P17987; P40227; P48643; P49368; P50990; P50991; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
CCT G beta 5 complex best PhLP1 class |
Heteromer O14775; P17987; P40227; P48643; P49368; P50990; P50991; Q13371; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
CCT-G beta 5 complex closed state 8 |
Heteromer O14775; P17987; P40227; P48643; P49368; P50990; P50991; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
CCT G beta 5 complex closed state 5 |
Heteromer O14775; P17987; P40227; P48643; P49368; P50990; P50991; Q13371; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
cryo-EM structure of human TRiC-ADP-AlFx |
Heteromer P17987; P40227; P48643; P49368; P50990; P50991; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
Human TRiC-tubulin-S3 |
Heteromer P07437; P17987; P40227; P48643; P49368; P50990; P50991; Q99832; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
cryo-EM structure of human TRiC-ATP-closed state |
Heteromer P17987; P40227; P48643; P49368; P50990; P50991; Q99832; | 100 | ||||
Human TRiC-PhLP2A complex in the closed state |
Heteromer P17987; P40227; P48643; P49368; P50990; P50991; Q99832; Q9H2J4; | 100 | 16×ADP; 16×MG; 16×AF3; | |||
Human TRiC/CCT complex with reovirus outer capsid protein sigma-3 |
Heteromer P03527; P17987; P40227; P48643; P49368; P50990; P50991; Q99832; | 100 | 1×ZN; | |||
Human TRiC in ATP/AlFx closed state |
Heteromer P17987; P40227; P48643; P49368; P50990; P50991; Q99832; | 100 | ||||
Cryo-EM structure of Human TRiC-ATP-open state |
Heteromer P17987; P40227; P48643; P49368; P50990; P50991; Q99832; | 100 | ||||
Cryo-EM structure of human TRiC-NPP state |
Heteromer P17987; P40227; P48643; P49368; P50990; P50991; Q99832; | 100.0 | ||||
Human TRiC open state |
Heteromer P17987; P40227; P48643; P49368; P50990; P50991; Q99832; | 100.0 | 6×ADP; | |||
Cryo-EM structure of human TRiC-tubulin-S2 |
Heteromer P17987; P40227; P48643; P49368; P50990; P50991; Q99832; | 100 | 16×ATP; | |||
cryo-EM structure of human TRiC-ADP |
Heteromer P17987; P40227; P48643; P49368; P50990; P50991; Q99832; | 100 | 16×ADP; | |||
hTRiC-hPFD Class3 |
Heteromer O15212; O60925; P17987; P40227; P48643; P49368; P50990; P50991; P61758; Q99471; Q99832; Q9NQP4; Q9UHV9; | 100 | ||||
hTRiC-hPFD Class6 |
Heteromer O15212; O60925; P17987; P40227; P48643; P49368; P50990; P50991; P61758; Q99471; Q99832; Q9NQP4; Q9UHV9; | 100 | ||||
hTRiC-hPFD Class5 |
Heteromer O15212; O60925; P17987; P40227; P48643; P49368; P50990; P50991; P61758; Q99471; Q99832; Q9NQP4; Q9UHV9; | 100 | ||||
hTRiC-hPFD Class1 (No PFD) |
Heteromer P17987; P40227; P48643; P49368; P50990; P50991; Q99832; | 100 | ||||
hTRiC-hPFD Class4 |
Heteromer O15212; O60925; P17987; P40227; P48643; P49368; P50990; P50991; P61758; Q99471; Q99832; Q9NQP4; Q9UHV9; | 100 | ||||
hTRiC-hPFD Class2 |
Heteromer O15212; O60925; P17987; P40227; P48643; P49368; P50990; P50991; P61758; Q99471; Q99832; Q9NQP4; Q9UHV9; | 100 | ||||
Human CCT:mLST8 complex |
Heteromer P17987; P40227; P48643; P49368; P50990; P50991; Q99832; | 100.0 | 2×ADP; | |||
Open state CCT-G beta 5 complex |
Heteromer P17987; P40227; P48643; P49368; P50990; P50991; Q99832; | 100.0 | 16×ADP; | |||
Cryo-EM structure of human TRiC-tubulin-S1 state |
Heteromer P17987; P40227; P48643; P49368; P50990; P50991; Q99832; | 100.0 | 6×ADP; | |||
Human TRiC-PhLP2A complex in the open state |
Heteromer P17987; P40227; P48643; P49368; P50990; P50991; Q99832; Q9H2J4; | 100 | 10×ADP; | |||
Human TRiC complex in open state with nanobody bound |
Heteromer P17987; P40227; P48643; P49368; P50990; P50991; Q99832; | 100.0 | 16×MG; 16×ADP; 12×AF3; | |||
Prefoldin-tubulin-TRiC complex |
Heteromer O15212; O60925; P17987; P40227; P48643; P49368; P50990; P50991; P61758; Q99471; Q99832; Q9NQP4; Q9UHV9; | 100 | 4×ADP; | |||
2 SWISS-MODEL models
Template | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
---|---|---|---|---|---|---|
7nvm.1.K | monomer | 0.70 | 1×ADP; 1×MG; 1×AF3; | 100.00 | ||
8ba8.1.A | homo-14-mer | 0.53 | 2×BEF; | 23.11 | ||
2 SWISS-MODEL models built on isoform sequence
Template | Isoform | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
---|---|---|---|---|---|---|---|
Isoform 2 | 7nvm.1.K | monomer | 0.71 | 1×MG; 1×AF3; | 100.00 | ||
Isoform 2 | 7xok.1.A | homo-14-mer | 0.52 | 21.94 | |||